Home > Proton Pump  & > Dexlansoprazole

Dexlansoprazole

右兰索拉唑,右旋兰索拉唑,T-168390,T168390,TAK 390,(R)-Lansoprazole,T 168390,TAK390,TAK-390

Dexlansoprazole是质子泵抑制剂，能抑制胃酸生成。

目录号
EY1419
EY1419
纯度
99.63%
99.63%
规格
100 mg
500 mg
原价
445
1200
售价
445
1200
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Metz DC, et al. Aliment Pharmacol Ther, 2009, 29(9), 928-937.

    分子式
    C16H14F3N3O2S    		 分子量
    369.36    		 CAS号
    138530-94-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    74 mg/mL    		 Water
    74 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01642602 Gastroesophageal Reflux Disease Drug: Dexlansoprazole Takeda Phase 2 2012-07-01 2014-07-14
    NCT02096458 Gastroesophageal Reflux Disease|Erosive Esophagitis|Heartburn Drug: Dexlansoprazole Takeda Phase 1 2014-02-01 2015-02-22
    NCT02064907 Bioavailability Drug: Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Drug: Dexlansoprazole Delayed Release Capsules Takeda Phase 1 2014-02-01 2015-03-30
    NCT02442752 Pediatric Gastroesophageal Reflux Disease Drug: Dexlansoprazole Takeda Phase 1 2016-02-01 2016-03-07
    NCT02162758 Barrett's Esophagus Drug: Dexlansoprazole|Drug: Dexlansoprazole Placebo Takeda Phase 4 2014-07-01 2016-08-23
    NCT02616302 Gastroesophageal Reflux Drug: Dexlansoprazole Takeda Phase 2 2015-11-01 2016-03-10
    NCT01637571 Chest Pain|Gastrointestinal Reflux Disease Drug: Dexilant|Drug: Dexilant Placebo University of Iowa Phase 4 2012-07-10
    NCT01317472 Laryngopharyngeal Reflux Drug: dexlansoprazole Indiana University 2011-03-01 2013-11-14
    NCT03087162 H Pylori Eradication Drug: Dexlansoprazole 60 mg once daily Ramathibodi Hospital Phase 4 2017-01-01 2017-03-15
    NCT02351960 Gastroesophageal Reflux Disease Drug: Dexlansoprazole 30 mg|Drug: Dexlansoprazole 60 mg Takeda Phase 4 2015-03-01 2016-07-21
    NCT01642615 Gastroesophageal Reflux Disease|Erosive Esophagitis Drug: Dexlansoprazole|Drug: Dexlansoprazole|Drug: Placebo Takeda Phase 2 2012-07-01 2015-05-08
    NCT02615184 Erosive Esophagitis Drug: Dexlansoprazole|Drug: Placebo Takeda Phase 2 2015-11-01 2016-03-10
    NCT00239551 Stomach Ulcer Drug: Prevacid Emory University|TAP Pharmaceutical Products Inc. Phase 4 2005-10-01 2013-07-29
    NCT00255190 Gastroesophageal Reflux Disease Drug: Dexlansoprazole MR|Drug: Dexlansoprazole MR Takeda Phase 3 2006-01-01 2016-06-27
    NCT02541786 Helicobacter Pylori Infection Drug: dexlansoprazole based triple therapy|Drug: rabeprazole-based triple therapy Kaohsiung Medical University Phase 4 2015-01-01 2015-09-01
    NCT00847210 Gastroesophageal Reflux Drug: Dexlansoprazole MR|Drug: Dexlansoprazole MR Takeda Phase 1 2009-05-01 2012-01-31
    NCT02873689 Heartburn|Gastroesophageal Reflux Disease Drug: Dexlansoprazole|Drug: Placebo Takeda Phase 3 2016-12-01 2017-01-26
    NCT01328652 Laryngopharyngeal Reflux|Hypertrophy of Lingual Tonsil Drug: dexlansoprazole Advanced Center for Specialty Care|Takeda Phase 4 2011-06-01 2011-04-04
    NCT03079050 GERD|Proton Pump Inhibitor Drug: Dexlansoprazole 30 MG|Drug: Dexlansoprazole 60 MG American University of Beirut Medical Center|Takeda Phase 3 2017-02-27 2017-03-08
    NCT00175045 Esophagitis|Reflux Drug: Lansoprazole|Drug: Lansoprazole Takeda Phase 2 2003-06-01 2010-07-20
    NCT00847808 Gastroesophageal Reflux Drug: Dexlansoprazole MR QD Takeda Phase 3 2009-02-01 2012-02-01
    NCT02529787 Healthy Drug: Doxirazole|Drug: Dexilant Genuine Research Center, Egypt|Hikma Pharma,Egypt Phase 1 2013-02-01 2015-08-19
    NCT00255151 Esophagitis, Reflux|Esophagitis, Peptic Drug: Dexlansoprazole MR|Drug: Dexlansoprazole MR|Drug: Placebo Takeda Phase 3 2006-01-01 2012-02-01
    NCT00255164 Esophagitis, Reflux|Esophagitis, Peptic Drug: Dexlansoprazole MR|Drug: Dexlansoprazole MR|Drug: Placebo Takeda Phase 3 2006-01-01 2012-02-01
    NCT00251758 Gastroesophageal Reflux Disease Drug: Dexlansoprazole MR|Drug: Dexlansoprazole MR|Drug: Placebo Takeda Phase 3 2005-12-01 2010-05-12

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：